Activation of the neuronal-glial network in the spinal cord dorsal horn (SCDH) mediates various chronic painful conditions. We studied spinal neuronal-astrocyte signaling interactions involved in the maintenance of painful diabetic neuropathy (PDN) in type 2 diabetes. We used the db/db mouse, an animal model for PDN of type 2 diabetes, which develops mechanical allodynia from 6 to 12 wk of age. In this study, enhanced substance P expression was detected in the presynaptic sensory fibers innervating lamina I-III in the lumbar SCDH (LSCDH) of the db/db mouse at 10 wk of age. This phenomenon is associated with enhanced spinal ERK1/2 phosphorylation in projection sensory neurons and regional astrocyte activation. In addition, peak phosphorylation of the NR1 subunit of N-methyl-D-aspartate receptor (NMDAR), along with upregulation of neuronal and inducible nitric oxide synthase (nNOS and iNOS) expression were detected in diabetic mice. Expression of nNOS and iNOS was detected in both interneurons and astrocytes in lamina I-III of the LSCDH. Treatment with MK801, an NMDAR inhibitor, inhibited mechanical allodynia, ERK1/2 phosphorylation, and nNOS and iNOS upregulation in diabetic mice. MK801 also reduced astrocytosis and glial acidic fibrillary protein upregulation in db/db mice. In addition, N(G)-nitro-L-arginine methyl ester (L-NAME), a nonspecific NOS inhibitor, had similar effects on NMDAR signaling and NOS expression. These results suggest that nitric oxide from surrounding interneurons and astrocytes interacts with NMDAR-dependent signaling in the projection neurons of the SCDH during the maintenance of PDN. V
INTRODUCTION
Diabetic neuropathy affects up to 50% of patients with type 1 or type 2 diabetes (Boulton et al., 2005; Feldman et al., 2005) . Among these patients, approximately 30% develop painful diabetic neuropathy (PDN; Davies et al., 2006) . Although PDN is a common symptom among diabetic patients, its mechanisms remain unclear. PDN is more prevalent in type 2 than in type 1 diabetes (Barrett et al., 2007) ; however, most published studies for PDN use animal models of type 1 diabetes. Understanding the mechanisms of PDN as it develops in the context of type 2 diabetes could lead to development of effective treatments to target the mechanisms behind this devastating disease. We have previously characterized the db/db mouse as a model for PDN of type 2 diabetes (Cheng et al., 2009) . The db/db mouse carries a homozygous null mutation of the leptin receptor (Hummel et al., 1966; Sullivan et al., 2007) . We reported that the db/db mouse develops features of PDN, including mechanical allodynia at 6-12 wk of age and evident sensory neuropathy at 24 wk of age (Cheng et al., 2009; Sullivan et al., 2007) . We reported that the initiation of mechanical allodynia in db/db mice is associated with early peripheral mechanisms, including increased NGF/Trk A receptor signaling in dorsal root ganglion (DRG) neurons before 8 wk of age. In this study, we report that these initial peripheral mechanisms activate the neuronal-glial interactions in spinal cord dorsal horn (SCDH) to mediate chronic PDN. Chronic pain is associated with enhanced spinal cord neuronal activity known as central sensitization (Latremoliere and Woolf, 2009) . It is well known that the neuronal N-methyl-D-aspartate receptor (NMDAR) mediates central sensitization in SCDH. In addition, regional microglial and astrocytic activation also contributes to chronic pain (Beggs and Salter, 2010; Gao and Ji, 2010b) . We demonstrated that increased peripheral nociceptive signals could lead to central spinal cord (SC) NMDAR-mediated neuron-astrocyte interactions. We tested the activation of NMDAR and related downstream nociceptive events, including ERK1/2 activation and enhanced nitric oxide synthase (NOS) levels in neuron and astrocytes in the lumbar SCDH (LSCDH). These signaling cascades are enhanced by nitric oxide (NO). Our findings provide new understanding of the molecular mechanisms of PDN of type 2 diabetes and indicate that blocking NMDAR and NO signaling could be effective treatments for PDN of type 2 diabetes.
MATERIALS AND METHODS Animals
Male C57BLKS db/db mice were purchased from Jackson Laboratories (Bar Harbor, Maine; stock number 000642). The homozygous (Lepr db /Lepr db or db/db) mice were used as a model of type 2 diabetes, whereas heterozygous mice (Lepr db /1 or db1) served as nondiabetic controls. Analyses and procedures were performed in compliance with protocols established by the Animal Models of Diabetic Complications Consortium (http://www.amdcc.org) and were approved by the Use and Care of Animals Committee at the University of Michigan.
Mechanical Allodynia
The animals were placed in a Plexiglass cage with mesh flooring and allowed to acclimatize for 1 h. A logarithmic series of calibrated monofilaments (Von Frey hairs; Stoelting, Wood Dale, IL) were applied to the midplantar surface of the hind paw and pressed to the point of bending. Brisk withdrawal of the stimulated paw was recorded as a positive response. Testing began with the 1 g filament followed by larger filaments, using the updown method (Dixon, 1980) . Although all responses were noted, counting of the critical six data points did not begin until the response threshold was first crossed. The resulting pattern of the six positive and negative responses was tabulated, and the 50% gram threshold was calculated using the formula described previously (Chaplan et al., 1994) .
Immunoblots
After deep anesthesia, L4-6 SC were dissected from four mice per condition (db/db and db1) and homogenized in ice-cold Tissue Protein Extraction Reagent, T-PER (Pierce Biotechnology, Rockford, IL) containing protease inhibitors (1 lM sodium orthovanadate and 1 lM sodium fluoride; Sigma Life Science, St. Louis, MO) and phosphatase inhibitors (13; Thermo Scientific, Rockford, IL). Fifty micrograms of protein was boiled in 23 sample buffer, separated on a sodium dodecyl polyacrylamide gel electrophoresis gel, and transferred to a polyvinylidene fluoride membrane. Membranes were blocked and incubated overnight at 4°C with primary antibodies: phospho-NR1 (pNR1, 1:1000, rabbit polyclonal; Millipore, Temecula, CA), total NR1 (1:1000, rabbit polyclonal; Millipore), phospho-extracellular signal-regulated kinases (pERK1/2, 1:1000; Millipore), total ERK1/2 (1:1000; Millipore), phospho-c-jun N-terminal kinase (pJNK, 1:1000; Millipore), total JNK (1:1000; Millipore), neuronal NOS (nNOS) (1:1000; Abcam, Cambridge, MA), inducible NOS (iNOS) (1:1000; Abcam), and glial acidic fibrillary protein (GFAP, 1:1000; Abcam). Membranes were then rinsed and incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h at 25°C and processed with chemiluminescence substrate (Pierce Biotechnology) before being exposed to Hyperfilm (Amersham, Piscataway, NJ). Densitometry was performed using Image J software, and the results were normalized against actin densities from the same sample.
Immunohistochemistry
Four mice from each group (db1 and db/db) were deeply anesthetized and perfused with 2% paraformaldehyde in phosphate-buffered saline (PBS; pH 7.2, 0.1 M). L4-6 SC were dissected, embedded in mounting media (OCT), and flash frozen in liquid nitrogen. Tissue sections (15 lm) were cut, rehydrated with PBS, and blocked in 0.1% TX-100 and 5% nonfat dry milk in PBS. For pERK1/2 and nNOS immunohistochemistry (IHC), sections were treated with hot citric acid (10 mM sodium citrate and 0.05% Tween 20, pH 6.0) for 3 min followed by rinsing with PBS. Sections were then incubated at room temperature for 16-24 h with primary antibodies: pERK1/2 (1:100), substance P (SP) (1:500, rat monoclonal; Abcam), nNOS (1:200), iNOS (1:100), and GFAP (1:1000; Abcam). Sections were then rinsed three times in PBS and incubated with secondary antiserum conjugated with different fluorophores (Alexa Fluor 488, 594, or 647; Invitrogen, Carlsbad, CA). Neurons were identified using NeuN antibody (1:250, Neuronal Nuclei, Alexa Fluor 488; Millipore). Fluorescent signals were examined using an Olympus FluoView 500 laser scanning confocal microscope. The percentage of immunopositive cells was analyzed by counting the number of immunopositive neurons and multiplying by (100/total number of neurons). A total of six lumbar spinal cord (LSC) sections from each animal were measured in a blinded fashion. Sections were incubated with primary antisera alone and secondary antisera alone to ensure specificity.
Inhibitor Treatments
Several reagents were used in the current study: an NMDAR antagonist, (5S,10R)-(-)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] acyclohepten-5,10-imine hydrogen maleate (MK801, 0.25 mg/kg, Sigma), or saline control were administered intraperitoneally. N-nitro-L-arginine methyl ester (L-NAME, 30 lg in 5 lL), a NOS inhibitor, or artificial cerebrospinal fluid (aCSF) was administered intrathecally 1 h before the behavior testing at 10 wk of age. The animals were given the second dose the next day, followed by perfusion and tissue collection 1 h after the second administration. The dose of the inhibitors used was based on published data [MK801 (Mao et al., 1992) and L-NAME (Meller et al., 1994; Zajac et al., 2000) ]. None of the drug treatments caused significant motor impairment or distress to the animals.
Minipump Placement
An osmotic minipump (Alzet minipump model 1007D, 100 lL volume with a 0.51 lL/h infusion rate; Duent Corporation, Cupertino, CA) was used for continuous intrathecal infusion into the LSC region. The minipumps were filled with aCSF with 10% dimethyl sulfoxide with or without mitogen-activated protein kinase (MAPK) (MEK) 1/2 inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis(oaminophenylmercapto) butadiene (UO126, 1 lg/lL; Calbiochem, La Jolla, CA), or aCSF (Obata et al., 2007) . The minipumps were implanted into the dorsal subcutaneous space between the shoulder blades of each mouse at 7 wk of age under sterile conditions. A cau- dally directed polyethylene cannula (Becton Dickinson and Company, Sparks, MD) was threaded subcutaneously and inserted into the subarachnoid space at the L5 level. The intrathecal infusion lasted for 1 wk at which time the mice reached 8 wk of age (Cheng et al., 2010) .
Data Presentation and Statistical Analyses
All data are presented as group means 6 SEM. The data between db1 and db/db mice of the same age were analyzed using the Mann-Whitney test. Statistical comparisons between different age groups were made by one-way analysis of variance tests followed by a post hoc Tukey's multiple comparison test. A P value of less than 0.05 was considered statistically significant.
RESULTS

Enhanced Presynaptic SP Inputs and Astrocytosis in the Superficial Lamina of the SCDH in db/db Mice
We previously determined that db/db mice develop mechanical allodynia from 6 to 12 wk of age (Cheng et al., 2009) . In this study, we hypothesized that increased SP release from presynaptic terminals triggers the neuronglial interactions in the SCDH of db/db mice to maintain chronic PDN. We studied SP IHC in SC from db1 and db/ db mice at 10 wk of age. In addition, we also performed IHC for GFAP to monitor the associated astrocytosis in LSCDH. In db1 mice, SP expression is mostly in presynaptic terminals of lamina I (Fig. 1A, arrowheads) . In db/ db mice, there is more extensive SP immunoreactivity in lamina I and II (Fig. 1D , arrowheads) and lamina III (Fig. 1D, asterisks) . In addition, increased numbers of Fig. 3 . Increased phosphorylation of NR1 and ERK1/2, but not JNK in the LSC of db/db mice. A: Representative immunoblots for pNR1 and total NR1. Increased NR1 phosphorylation was detected from 8 to 16 wk of age, with maximal pNR1 levels detected at 10 wk of age. B: Densitometric analysis of NR1 phosphorylation. A 2.5-fold increase in NR1 phosphorylation was detected at 10 wk of age. C: Representative immunoblots for pERK1/2 and total ERK1/2. Increased ERK1/2 phosphorylation was detected from 8 to 16 wk of age with maximum pERK1/2 levels detected at 10 wk of age. D: Densitometric analysis of ERK1/2 phosphorylation. A threefold increase in ERK1/2 phosphorylation was detected at 10 wk of age. E: Representative immunoblots for pJNK and total JNK. F: Densitometric analysis of JNK phosphorylation. No significant change of JNK phosphorylation was detected in db/db mice. *P < 0.05; **P < 0.01. N 5 4.
GFAP-positive astrocytes were detected in lamina I-III in db/db mice (compare Fig. 1B to Fig. 1E , arrows). These astrocytes were larger and with long processes, indicating they were activated astrocytes (Fig. 1E , arrows).
Increased pERK1/2-Positive Neurons in Superficial Lamina of SCDH in db/db Mice
To demonstrate the activation of postsynaptic SCDH neurons at the same stage, we performed double IHC for SP and pERK1/2 using LSC sections from 10-wk-old mice (Fig. 2) . SP IHC demonstrated presynaptic nociceptive fibers in SCDH ( Fig. 2A,D) . Only minimal levels of pERK1/2 expressed in the LSCDH of db1 mice was observed (Fig. 2B, arrow) . In contrast, intense pERK1/2 immunoreactivity was detected in neurons of lamina I-III in db/db mice (Fig. 2E ,F, arrows).
Phosphorylation of Nr1 and Erk1/2 During the Period of Mechanical Allodynia
We hypothesized that NMDAR signaling is the key mechanism for the neuron-glial activation in SCDH. To Fig. 4 . Upregulation of nNOS expression in db/db mice. A: Representative nNOS immunoblots used proteins from the LSC of db1 and db/db mice. Increased nNOS expression was detected in db/db mice at 10 wk of age. B: Densitometric analysis of nNOS immunoblots. There was a 1.8-fold increase of nNOS expression in db/db mice compared with db1 mice at 10 wk of age. C-K: Increased nNOS immunoreactivity was detected in neurons and astrocytes in db/db mice. C-E: Few nNOS-positive neurons were detected in lamina II (arrows) and III (arrowheads) in db1 mice. F-H: Increased numbers of nNOS-positive neurons were detected in laminas II (arrows) and III (arrowheads) of LSCDH of db/db mice. In addition, glial cell processes (G, asterisks) were observed to be nNOS positive. I-K: High-power confocal images identified nNOS-positive astrocytes. The nNOS-positive glial cells (J, arrows) expressed GFAP (I, arrows) and were identified as astrocytes (K, arrows). **P < 0.01. N 5 4. C-H, Bar 5 20 lm; I-K, Bar 5 5 lm.
test our hypothesis, we first studied the activation of NMDAR during the period of mechanical allodynia in db/db mice. N-methyl-D-aspartate (NMDA) activation is determined using immunoblots of pNR1. As demonstrated in Fig. 3A , enhanced NR1 phosphorylation was detected at 8 and 10 wk of age in db/db mice compared with db1 mice of the same age. The total NR1 signals on the same immunoblots demonstrated unchanged total NR1 protein levels, and actin signals were used as corresponding loading controls. Densitometric studies determined that there were enhanced pNR1 levels at 8-12 wk of age with the maximal NR1 phosphorylation detected at 10 wk of age with a 2.5-fold increase over the control db1 mice (Fig. 3B ). NR1 phosphorylation was not detected before diabetes (at 5 wk). Although its levels were reduced, the pNR1 signal remained above the control level after the period of mechanical allodynia (at 16 wk). The levels of ERK1/2 phosphorylation were determined by pERK1/2 immunoblots (Fig. 3C ). In accordance with NR1 phosphorylation, enhanced pERK1/2 levels in SC were detected at 8-16 wk of age, with maximal levels of phosphorylation detected at 10 wk of age (Fig. 3C) . ERK1/2 immunoblots demonstrated unchanged total protein expression, and actin immunoblots served as loading controls. Densitometric analysis demonstrated that enhanced pERK1/2 levels were detected from 8 to 16 wk of age, with a peak at 10 wk of age in db/db mice. Enhanced pERK1/2 levels were not detected at 5 wk of age, before onset of diabetes. Nevertheless, significant ERK1/2 phosphorylation was still detectable at 16 wk of age (Fig. 3D) . Unlike NR1 and ERK1/2, there was no change in JNK phosphorylation in the LSC of db/db mice compared with db1 controls during the tested periods (Fig. 3E,F) .
Increased nNOS Expression in Neurons and
Astrocytes of the SCDH in db/db Mice Another NMDAR-dependent nociceptive pathway is nNOS signaling (Freire et al., 2009) . As the second step, we studied nNOS expression during the period of mechanical allodynia using immunoblots (Fig. 4A,B) . A sig- nificant increase of nNOS levels was detected at 10 wk of age. In parallel, the cell-specific distribution of nNOS was examined by IHC, demonstrated in Fig. 4C -H. Increased nNOS immunoreaction was detected in neurons of lamina II and III in SCDH of db/db mice (Fig.  4G,H) . Similarly, nNOS was detected in GFAP-positive astrocytes (Fig. 4I-K) .
Increased iNOS Expression in Astrocytes of the SCDH in db/db Mice
We examined the expression of iNOS during the period of mechanical allodynia in the LSCDH of db1 and db/db mice by immunoblots (Fig. 5A) . iNOS expression was upregulated at 10 wk of age, with a 3.3-fold increase in db/db mice over that of db1 controls (Fig. 5A,B) . In contrast to nNOS, immunoreactivity of iNOS was detected only in astrocytes and not in neurons on lamina I-III of the SCDH (Fig. 5C-H) .
Effects of MK801, UO126, and L-NAME Treatments on Mechanical Allodynia in db/db Mice
To determine whether NR1, ERK1/2, nNOS, and iNOS are important for the development of mechanical allodynia at 10 wk of age, we treated db/db mice and control mice with inhibitors for each pathway. First, MK801, a NMDAR inhibitor, was administered to both db1 and db/db mice at 10 wk of age. MK801 treatment significantly reduced the degree of decreased mechanical thresholds in db/db mice, reversing mechanical allodynia in db/db mice (Fig. 6A) . Second, UO126, a MAPK inhibitor, was administered intrathecally for 7 d to both db1 and db/db mice at 9 wk of age by using implanted minipumps. Similar to MK801 treatment, UO126 treatment significantly reversed mechanical allodynia in db/db mice (Fig. 6B) . Finally, L-NAME, a nonspecific NOS inhibitor that blocks actions of both nNOS and iNOS, was injected intrathecally at 10 wk of age. In addition to MK801 and UO126, L-NAME treatment significantly reduced mechanical allodynia in db/db mice (Fig. 6C) .
Effects of MK801 on Enhanced pNR1, pERK, nNOS, and iNOS Levels in the LSC of db/db Mice To determine how these signaling events contribute to the maintenance of mechanical allodynia in db/db mice, we studied the effects of these three inhibitors on NR1 and ERK1/2 phosphorylation and nNOS and iNOS upregulation. First, we tested the effects of MK801. Immunoblot analysis demonstrated that MK801 treatment significantly reduced NR1 (Fig. 7A,B ) and ERK1/2 phosphorylation (Fig. 7C,D) . In addition, MK801 treatment inhibited the upregulation of nNOS (Fig. 7E,F) and iNOS (Fig. 7G,H ) expression in db/db mice. In contrast, MK801 treatment did not affect pERK1/2 and NOS levels in db1 mice.
Furthermore, MK801 treatment significantly reduced the number of pERK1/2-and nNOS-positive neurons in the LSCDH of db/db mice (Fig. 8) . Consistent with Figs. 3 and 4, pERK1/2 and nNOS were detected in neurons in the corresponding lamina of the LSCDH in db/db mice (Fig. 8B,C) . Although MK801 treatment did not affect the SP immunoreactivity in db/db mice (Fig. 8A,D) , it significantly reduced the number of pERK1/2-positive (Fig. 8B,E) and nNOS-positive (Fig. 8C,F ) neurons in LSCDH of db/db mice. Quantitative analyses revealed significant reductions of pERK1/2-positive (Fig. 8G ) and nNOS-positive (Fig.  8H ) neurons after MK801 treatment in the LSCDH of db/db mice. Fig. 6 . MK801, UO126, and L-NAME inhibit mechanical allodynia in db/db mice. A: MK801 treatment significantly reversed decreased mechanical thresholds in db/db mice to control levels. B: UO126 treatment significantly reversed decreased mechanical thresholds in db/db mice to the levels of control db1 mice. C: L-NAME treatment significantly reversed decreased mechanical thresholds in db/db mice to the control levels. **P < 0.01. N 5 4.
Effects of MK801 on Astrocytosis in the LSC of db/db Mice
In addition to inhibition of neuronal activity, MK801 treatment reduced astrocytosis in the LSCDH of db/db mice (Fig. 9) . GFAP immunoblot analysis detected a threefold increase of GFAP expression in the LSC of control-treated db/db mice in comparison with db1 mice of the same condition (Fig. 9A,B) . MK801 treatment significantly reduced the GFAP levels of db/db mice to the db1 levels (Fig. 9A,B) . In parallel, GFAP IHC also demonstrated reduced numbers of astrocytes in the LSCDH of db/db after MK801 treatment (Fig. 9E,F) . Fig. 7 . MK801 inhibits NR1 and ERK1/2 phosphorylation and nNOS and iNOS upregulation in db/db mice. A: Representative immunoblots of pNR1, total NR1, and actin from the LSC of db1 and db/db mice treated with control solution (C) or MK801. MK801 treatment decreased NR1 phosphorylation in db/db LSC and had no effect on db1 mice. B: Densitometric analysis of pNR1 immunoblots. MK801 treatment decreased levels of NR1 phosphorylation back to control levels. C: Representative immunoblots of pERK1/2, total ERK1/2, and actin from LSC of db1 and db/db mice treated with control solution (C) or MK801. MK801 treatment decreased ERK1/2 phosphorylation in db/db but not in db1 mice. D: Densitometric analysis of pERK1/2 immunoblots. MK801 treatment decreased the levels of ERK1/2 phosphorylation back to control levels. E: nNOS immunoblots revealed that MK801 treatment reduced nNOS upregulation in db/db mice. F: Densitometric analysis of nNOS immunoblots demonstrated that MK801 treatment decreased nNOS levels in db/db mice back to control levels. G: iNOS immunoblots showed that MK801 treatment reduced iNOS upregulation in db/db mice. H: Densitometric analysis of iNOS immunoblots demonstrated that MK801 treatment decreased iNOS levels in db/db mice back to control levels. *P < 0.05; **P < 0.01. N 5 4.
Effects of UO126 on Enhanced pERK, nNOS, and iNOS Levels in the LSC of db/db Mice
As expected, intrathecal UO126 treatment significantly inhibited ERK1/2 phosphorylation in db/db mice (Fig. 10A,B) . However, UO126 treatment had no effect on increased levels of nNOS (Fig. 10C,D) and iNOS (Fig.  10E,F) in db/db mice. In addition, UO126 treatment had no significant effects on pERK1/2, nNOS, or iNOS levels in db1 mice.
Effects of L-NAME on Enhanced pNR1, pERK, nNOS, and iNOS Levels in LSC of db/db Mice Similar to MK801, L-NAME treatment significantly reduced NR1 (Fig. 11A,B ) and ERK1/2 phosphorylation (Fig. 11C,D) in db/db mice. L-NAME treatment had no effects on control levels of pNR1 and pERK1/2 in db1 mice. In addition, L-NAME treatment reduced levels of nNOS (Fig. 11E,F) and iNOS (Fig. 11G,H ) in db/db mice, but not in db1 mice.
DISCUSSION
PDN is a prevalent cause of chronic neuropathic pain in patients with type 2 diabetes. In our current report, we study the involvement of spinal neuron-astrocyte signaling for enhanced nociception in PDN of type 2 diabetes. Our current findings suggest that increased peripheral nociceptive input is essential for the subsequent development of SC mechanisms for mechanical allodynia (Cheng et al., 2009 ). This notion is supported by Latremoliere and Woolf (2009) , who reviewed the literature and recognized that increased levels of subthreshold synaptic inputs to SCDH nociceptive neurons could induce central neural plasticity.
Our results indicate that ERK1/2 phosphorylation occurred in neurons in lamina I-III of the LSC during the maintenance phase of mechanical allodynia in db/db mice. These results are consistent with published data from models of inflammatory pain (Cheng et al., 2008; Gao and Ji, 2010a) and pain from electric stimulation (Lever et al., 2003) , capsaicin treatment (Ji et al., 1999) , and nerve injuries (Obata et al., 2004) . Our data suggest that increased ERK phosphorylation is associated with increased presynaptic SP secretion. In support of our hypothesis, Ji et al. (2002) reported that NK1, the SP receptor, is colocalized with activated ERK in painful conditions. In addition, Kawasaki et al. (2004) directly applied SP to SC, which in turn induced spinal ERK activation.
In the current report, we discovered increased astrocytosis in the LSCDH, suggesting increased neuronalastrocyte interaction during the maintenance phase of mechanical allodynia in db/db mice. Comparable to our data, Liao et al. (2011) reported astrocyte activation in LSCDH of db/db mice at the same age. In addition, astrocyte activation has been reviewed in various animal models for both inflammatory and neuropathic pain (Gao and Ji, 2010b) . In contrast to astrocyte activation, we failed to detect microglial activation using either OX42 or Iba1 IHC (data not shown) consistent with the findings of Liao et al. (2011) that minocycline did not affect the mechanical allodynia in db/db mice.
NMDAR activation is a well-known mechanism to mediate central sensitization for prolonged and enhanced nociception in animal models of inflammatory and neuropathic pain (Woolf, 2007) . However, evidence of spinal NMDAR activation in PDN of type 2 diabetes is still lacking. On the basis of a plethora of published evidence in other pain models (Mao et al., 1992; Persson et al., 1995; Ren et al., 1992) , we studied the roles of NMDAR and its downstream signaling pathways for the maintenance of mechanical allodynia in the db/db mouse, an animal model of type 2 diabetes. In addition Fig. 9 . MK801 inhibits GFAP expression and astrocytosis in db/db mice. A: GFAP immunoblots used protein samples from the LSC of db1 and db/db mice treated with control or MK801. Increased amount of GFAP protein was detected in control-treated db/db mice. The GFAP upregulation in db/db mice was inhibited by MK801 treatment. B: Densitometric analysis of GFAP immunoblots demonstrated that MK801 treatment decreased GFAP levels in db/db mice back to that of db1 mice. **P < 0.01. N 5 4. C-F: MK801 treatment reduced the degree of astrocytosis in db/db mice. Increased number of astrocytes in the LSCDH in control-treated db/db mice (arrows, compare C and E) was reduced by MK801 treatment (arrows, compare E and F). Bar 5 20 lm, N 5 4.
to the current study, Liao et al. (2011) reported a similar time course of NR1 phosphorylation in the db/db mouse model. A majority of other published studies for spinal mechanisms in PDN have been performed in models of type 1 diabetes. Daulhac et al. (2006) reported that there are NMDAR-dependent activation of MAPKs, including ERK1/2, p38, and JNK, in the LSC at 21 days after induction of type 1 diabetes by streptozotocin (STZ) treatment. In addition, Rondon et al. (2010) detected NR1 phosphorylation in the LSC in the STZ rat model 4 wk after diabetes. In their report, magnesium sulfate treatment, which served as an inhibitor for NMDAR, not only suppressed NR1 phosphorylation but also decreased pain behaviors in diabetic animals. These reports indicate that NMDAR activation could be a mechanism for PDN in both type 1 and type 2 diabetes.
Our current results demonstrated upregulation of nNOS in the SCDH. We observed nNOS expression in neurons and astrocytes of lamina II and III. These results are consistent with a previous report by Ruscheweyh et al. (2006) . In their report, nNOS-positive neurons are mostly interneurons, similar to our current findings. Interestingly, neurons that contain soluble guanylyl cyclase, the target molecule of NO, are distributed mostly in lamina I and II. They concluded that NO diffused from the nNOS-positive interneurons to act on projection neurons in lamina I. On the basis of immunohistochemical distribution of nNOS in db/db mice, we speculate that similar mechanisms might be involved in PDN of type 2 diabetes. However, these mechanisms might not be associated with PDN of type 1 diabetes. For example, Vareniuk et al. (2009) detected reduced thermal hyperalgesia, but not mechanical allodynia in STZ-treated nNOS knockout mice compared with diabetic wild-type mice. Unfortunately, iNOS expression was not studied in their report. In addition, Bujalska et al. (2008) reported that iNOS, but not nNOS, is involved in PDN of STZ rats by using specific NOS inhibitors. In our current report, we detected increased expression of both nNOS and iNOS in db/db mice. To block both NOS Fig. 10 . UO126 has no effect on nNOS and iNOS expression. A: Representative immunoblots of pERK1/2, total ERK1/2, and actin from the LSC of db1 and db/db mice intrathecally treated with control aCSF (C) or aCSF with UO126. UO126 treatment decreased ERK1/2 phosphorylation in db/db but not in db1 mice. B: Densitometric analysis of pERK1/2 immunoblots. UO126 treatment decreased the levels of ERK1/ isoforms, we used L-NAME, a nonspecific NOS inhibitor. We acknowledge that L-NAME treatment only provides information for general NOS-mediated actions. Further studies using specific NOS inhibitors are necessary to elucidate whether nNOS and/or iNOS mediate PDN in type 2 diabetes.
In the current report, we detected expression of iNOS in astrocytes of lamina I. Similar to our findings, iNOS expression is reported in a variety of pain models for both inflammatory and neuropathic pain (Freire et al., 2009 ). In the SCDH, astrocyte-derived iNOS was implicated in presynaptic potentiation, a form of long-term Fig. 11 . L-NAME inhibits NR1 and ERK1/2 phosphorylation and nNOS and iNOS upregulation in db/db mice. A: Representative immunoblots of pNR1, total NR1, and actin from the LSC of db1 and db/db mice intrathecally treated with control aCSF (C) or aCSF with L-NAME. L-NAME treatment decreased NR1 phosphorylation in db/db but not in db1 mice. B: Densitometric analysis of pNR1 immunoblots. L-NAME treatment decreased the levels of NR1 phosphorylation back to that of control db1 mice. C: Representative immunoblots of pERK1/ 2, ERK1/2, and actin from the LSC of db1 and db/db mice treated with control solution (C) or L-NAME. L-NAME treatment decreased ERK1/2 phosphorylation in db/db but not in db1 mice. D: Densitometric analysis of pERK1/2 immunoblots. L-NAME treatment decreased the levels of ERK1/2 phosphorylation back to control levels. E: nNOS immunoblots revealed that L-NAME treatment reduced nNOS upregulation in db/db mice. F: Densitometric analysis of nNOS immunoblots demonstrated that L-NAME treatment decreased nNOS levels in db/db mice back to control levels. G: iNOS immunoblots showed that L-NAME treatment reduced iNOS upregulation in db/db mice. H: Densitometric analysis of iNOS immunoblots demonstrated that L-NAME treatment decreased iNOS levels in db/db mice back to control levels. **P < 0.01; ***P < 0.001. N 5 4. potentiation, to enhance nociception (Amitai, 2010) . The current findings suggest that a similar phenomenon could exist in the SCDH of db/db mice to mediate mechanical allodynia.
Our findings indicate that ERK1/2 phosphorylation is a NMDAR-dependent event. Several studies have shown that glutamate transmission through NMDARs is essential for ERK activation in SCDH neurons (Ji et al., 1999; Lever et al., 2003) . Analogous to our findings, Daulhac et al. (2006) reported not only ERK1/2 but also p38 and JNK activation in STZ-treated rats. Conversely, we failed to detect the activation of JNK and p38 (data not shown) in the LSC of db/db mice. In addition, we did not detect pERK1/2 immunoreactivity in microglia as reported in the study by Daulhac et al. (2006) . This discrepancy could reflect a distinction in the SC mechanisms that mediate PDN in type 1 and type 2 diabetes or a species-specific difference between these studies. We are currently investigating NMDAR and MAPK activation in PDN of STZ-treated db1 mice to better understand the cause of these discordant observations.
In accord with other studies, our data demonstrated that ERK1/2 phosphorylation is mostly located in the superficial layers (lamina I-III) of the SCDH (Ji et al., 2009) . We speculate that these pERK1/2-positive neurons are projection neurons that provide the spinothalamic tract. In agreement with our hypothesis, Slack et al. (2005) identified the activation of ERK1/2 in the Trk B-positive SCDH projection neurons that provide the spinothalamic tract after brain-derived neurotrophic factor treatment. The current findings that demonstrated UO126 inhibition of mechanical allodynia without affecting the increased nNOS and iNOS levels suggest that pERK1/2-positive neurons are likely the projec-tion neurons that integrate the actions of NO from neighboring interneurons and astrocytes in the SCDH and transmit nociceptive signals to the higher levels of the central nervous system.
Our data suggested MK801 treatment inhibited both nNOS and iNOS expression. Unfortunately, little has been published about NMDAR-mediated NOS expression aside from our current report. In the enteric nervous system, MK801 treatment inhibited the upregulation of nNOS in the enteric plexus after ischemia-reperfusion (Calcina et al., 2005) . In addition, MK801 treatment reduced increased SC nNOS levels in morphine tolerance (Wong et al., 2000) . After traumatic SC injury, MK801 treatment reduced inflammatory reactions, including enhanced iNOS expression and improved function recovery (Esposito et al., 2011) . A similar phenomenon was also observed after hypoxic brain injury (Jander et al., 2000) . Our results suggest that similar NMDAR-mediated NOS expression is involved in interneurons for the mediation of PDN of type 2 diabetes. Specifically, this signaling event occurs in interneurons of lamina II and III and is ERK-independent.
Our data indicated that MK801 inhibited the enhanced astrocytosis in SCDH of db/db mice. These findings suggest that NMDAR signaling mediates local astrocyte activation. In the literature, several NMDARdependent factors, such as chemokines, and cytokines, are reported to mediate enhanced astrocytosis in a central pain model after spinal cord injury (Gwak et al., 2012) . Our studies provide evidence that similar mechanisms could be associated with PDN in type 2 diabetes.
Our results from L-NAME treatment suggest that NO is essential for the maintenance of mechanical allodynia in db/db mice. In support of our findings, spinal NO was reported to mediate NMDA-induced hyperalgesia in other pain models. For example, Kitto et al. (1992) observed inhibition of NMDA-induced hyperalgesia as a result of intrathecal L-NAME treatment. Increased NOS expression was also reported in an inflammatory pain model (Infante et al., 2007) . In addition, L-NAME inhibits neuropathy-induced thermal hyperalgesia (Inoue et al., 1998; Thomas et al., 1996) .
Our data suggest that NO mediates increased NR1 and ERK1/2 phosphorylation. Because pERK1/2 is mostly located in the projection neurons of lamina I-III, distinct from nNOS-positive interneurons, these results indicate that there is NO-mediated NMDAR activation in projection neurons. In support of our hypothesis, Malmberg and Yaksh (1993) reported that intrathecal L-NAME treatment blocked the second phase of pain from the formalin test and NMDA-induced thermal hyperalgesia, suggesting NO enhances NMDAR actions. In addition, Sorkin (1993) reported that L-NAME treatment directly inhibits increased levels of glutamate and citrulline, an amino acid co-product of NO synthesis, in response to spinal administration of NMDA. Other than indirectly enhancing pERK1/2 levels through increased NMDAR activation, NO could also trigger ERK1/2 phosphorylation by mechanisms independent of NMDAR signaling. Komatsu et al. (2009) reported that NO mediates morphine-3-glucuronide-induced pain through the NOcGMP-PKG pathway. Because MK801 completely blocks increased pERK1/2 levels in our current study, NO-dependent ERK1/2 activation is less likely to occur in our model. Similar to NO, interleukin (IL)-1b also contributes to enhanced NMDAR phosphorylation in db/db mice, suggesting that multiple factors are involved in this action (Liao et al., 2011) . Both NO and IL-1b-mediated NMDAR phosphorylation is likely triggered by reactive oxygen species generated from type 2 diabetes (Liao et al., 2011) .
In addition to increased nNOS and iNOS expression in the SCDH, we detected evidence that there is NMDAR-mediated ERK1/2 activation during the maintenance phase of mechanical allodynia in db/db mice. Our data suggest that increased NMDAR-pERK1/2 signaling in projection neurons is an essential step for the maintenance of mechanical allodynia in db/db mice. In addition, increased NOS expression in nearby interneurons and astrocytes further serves as a positive feedback mechanism to enhance NMDAR activation by NO (Model 1). This model is different from the one proposed by Liao et al., who suggested a one-way mechanism where astrocyte-derived IL-1b induces neuronal NMDAR activation and mechanical allodynia. In contrast, our model suggests a more complicated neuron-astrocyte network to mediate PDN in type 2 diabetes.
